Servei de Neurologia-Neuroimmunologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Memory Unit, Department of Neurology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
Mult Scler. 2019 Oct;25(11):1535-1538. doi: 10.1177/1352458518786055. Epub 2018 Jul 9.
The role of cerebrospinal fluid (CSF) mitochondrial DNA (mtDNA) levels as biomarker in multiple sclerosis (MS) is unknown. We determined CSF mtDNA levels in a cohort of 237 individuals, including patients with MS and clinically isolated syndrome (CIS), inflammatory and non-inflammatory neurological controls, and cognitively healthy controls (HC). mtDNA concentration was measured by droplet digital polymerase chain reaction. CSF mtDNA levels were increased in all pathological conditions compared with HC, though no differences were observed between relapse-onset and progressive MS clinical forms, CIS patients and neurological controls. These findings do not support the determination of CSF mtDNA levels as a useful biomarker in MS clinical practice.
脑脊液（CSF）线粒体 DNA（mtDNA）水平作为多发性硬化症（MS）生物标志物的作用尚不清楚。我们在包括 MS 和临床孤立综合征（CIS）、炎症性和非炎症性神经学对照以及认知健康对照（HC）在内的 237 名个体的队列中确定了 CSF mtDNA 水平。通过液滴数字聚合酶链反应测量 mtDNA 浓度。与 HC 相比，所有病理条件下的 CSF mtDNA 水平均升高，但复发型和进展型 MS 临床形式、CIS 患者和神经学对照之间未见差异。这些发现不支持将 CSF mtDNA 水平作为 MS 临床实践中有用的生物标志物进行测定。
